Cancer therapy targeting the fibrinolytic system

Adv Drug Deliv Rev. 2016 Apr 1;99(Pt B):172-179. doi: 10.1016/j.addr.2015.11.010. Epub 2015 Nov 14.

Abstract

The tumor microenvironment is recognized as a key factor in the multiple stages of cancer progression, mediating local resistance, immune-escape and metastasis. Cancer growth and progression require remodeling of the tumor stromal microenvironment, such as the development of tumor-associated blood vessels, recruitment of bone marrow-derived cells and cytokine processing. Extracellular matrix breakdown achieved by proteases like the fibrinolytic factor plasmin and matrix metalloproteases is necessary for cell migration crucial for cancer invasion and metastasis. Key components of the fibrinolytic system are expressed in cells of the tumor microenvironment. Plasmin can control growth factor bioavailability, or the regulation of other proteases leading to angiogenesis, and inflammation. In this review, we will focus on the role of the fibrinolytic system in the tumor microenvironment summarizing our current understanding of the role of the fibrinolytic factors for the modulation of the local chemokine/cytokine milieu, resulting in myeloid cell recruitment, which can promote neoangiogenesis.

Keywords: CXCL5; Cancer; Chemokine; Inflammation; MCP-1; Matrix metalloproteinase; Microenvironment; Plasmin.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cell Movement / drug effects
  • Disease Progression
  • Fibrinolysis / drug effects*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Myeloid Cells / drug effects
  • Myeloid Cells / pathology
  • Neoplasms / drug therapy*
  • Neoplasms / pathology*
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / pathology
  • Tumor Microenvironment / drug effects

Substances

  • Fibrinolytic Agents